HLS Healius Ltd
- 1.440
- +0.020+1.41%
Healius Ltd News
3 ASX 200 Stocks Leading the Charge Higher in June
Three S&P/ASX 200 Index (ASX: XJO) stocks are doing more than their fair share to get the benchmark index off to a strong start in June.
Healius Hires UBS to Sell Lumus Imaging
Healius (ASX:HLS) has appointed UBS to sell its diagnostic imaging division, Lumus Imaging, as part of a recently completed strategic review, according to a Monday Australian bourse filing. The sale i
Healius Ltd Director's Shareholding Adjustment
Why Fletcher Building, Healius, Iperionx, and Iress Shares Are Sinking Today
The S&P/ASX 200 Index (ASX: XJO) is having a strong session on Wednesday. At the time of writing, the benchmark index is up 0.5% to 7,763.8 points.
Healius's Covenants Suggest Downturn in Operating Conditions -- Market Talk
2321 GMT - Pathology services provider Healius's increase to its near-term loan covenants could suggest operating conditions have worsened, Morgan Stanley says. In a note, analyst Sean Laaman says Hea
Healius Refinances Debt Facility to March 2027
Healius (ASX:HLS) refinanced a tranche of its syndicated debt facility to March 2027. As part of the refinancing, the healthcare company scaled back the demand and the size of the tranche to AU$180 mi
AU Evening Wrap: Australia Shares Rise 0.7%, Led by Real-Estate Stocks
Property trusts were the best performing sector, rising 1.8%.
Healius May Not Get the Strong 4Q It Needs -- Market Talk
2140 GMT - Pathology services provider Healius is banking on a strong 4Q to achieve its earnings guidance, but Jefferies is skeptical it can get there. In a note, analyst David Stanton says Healius's
Healius Price Target Cut 1.7% to A$1.18/Share by Jefferies
Healius Price Target Cut 1.7% to A$1.18/Share by Jefferies
Morgan Stanley Adjusts Healius' Price Target to AU$1 From AU$1.30, Keeps at Underweight
Healius (ASX:HLS) has an average rating of underperform and price targets ranging from AU$1 to AU$3, according to analysts polled by CapitalIQ. Price (AUD): $1.26, Change: $-0.03, Percent Change: -2.3
Healius Could Solve Near-Term Gearing Issue With Imaging Sale -- Market Talk
0101 GMT - Healius could solve its near-term gearing challenges by selling its imaging business, Citi analyst Mathieu Chevrier writes in a note. A sale of the imaging business could be the most likely
Healius Begins Strategic Review of Assets, Structure Under New CEO
ustralian pathology and imaging provider Healius has begun a strategic review of its assets and structure that it said would be aimed at maximizing shareholder value.
AU Morning Wrap: Gold Miners Shine, Healius Up 11% on New CEO
Stocks to watch: Healius, St Barbara, Telix.
Beaten-up ASX 200 Stock Jumps 14% on CEO Resignation
Healius Ltd (ASX: HLS) shares are storming higher on Tuesday morning.
Healius Needs Pathology to Step Up to Stay Within Covenants -- Market Talk
0021 GMT - Barrenjoey puts pathology-services provider Healius's gearing under the microscope following its 1H result. Barrenjoey now forecasts Ebitda of A$345.1 million in FY 2024, representing a 2%
Healius Downgraded to Sell From Neutral by Citi
Healius Downgraded to Sell From Neutral by Citi
Healius Target Price Cut 3.6% to A$1.35/Share by Macquarie>HLS.AU
Healius Target Price Cut 3.6% to A$1.35/Share by Macquarie>HLS.AU
Australian Shares Inch Up as Market Awaits Economic Data, US Fed Statements
Australian shares inched up on Tuesday as the market awaited the release of local and international economic data and statements from US Federal Reserve members. The S&P/ASX 200 Index rose 10.20 point
Healius Price Target Cut 4% to A$1.20/Share by Jefferies
Healius Price Target Cut 4% to A$1.20/Share by Jefferies
2 Popular ASX 200 Healthcare Shares Tanking on Earnings Updates
As earnings season rolls on, let's take a look at the reports for popular ASX 200 healthcare shares Polynovo Ltd (ASX: PNV) and Healius Ltd (ASX: HLS).
Analysis
Price Target
No Data
